Neuboron Medical Group

Executive Summary

Neuboron Medical Group is a China-based pioneer in Boron Neutron Capture Therapy (BNCT), a targeted radiotherapy modality for locally invasive and recurrent tumors. The company develops proprietary neutron sources, boron delivery agents, and treatment planning systems to enable precise cancer cell destruction while sparing healthy tissues. BNCT offers potential advantages over conventional radiotherapy, particularly for refractory cancers. Currently in Phase 2 clinical development, Neuboron is advancing its integrated BNCT system and boron drug candidates. If successful, it could address significant unmet needs in glioblastoma, head and neck cancers, and other hard-to-treat malignancies. The company benefits from China's supportive regulatory environment for innovative medical devices and radiopharmaceuticals. Key risks include technical challenges in neutron source miniaturization and boron drug biodistribution, as well as competition from other BNCT developers globally.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical data readout for BNCT system in glioblastoma60% success
• H1 2027Regulatory approval of boron drug for BNCT in China50% success
• Q2 2026Strategic partnership or licensing deal with global pharma40% success